Operationalizing Screening for Non-Small Cell Lung Cancer: An International Discussion - Episode 4
International Dialogue on Which Biomarkers to Prioritize in NSCLC Testing
Experts underscore that comprehensive biomarker testing is now essential not just for stage IV non-small cell lung cancer (NSCLC), but also for earlier stages, starting from stage 1b. This is driven by the approval of adjuvant targeted therapies and neoadjuvant regimens, making molecular profiling critical for curative-intent treatment planning.
The panel affirms that the standard of care is to run a full NGS panel upfront to avoid delays. They discuss that while some biomarkers like KRAS mutations can halt the search for other drivers, a complete profile is ideal. Critically, they highlight how test results directly influence major decisions; for instance, finding an ALK alteration rules out checkpoint inhibitor use and may steer treatment towards surgery followed by adjuvant targeted therapy. The conversation concludes by noting that biomarker panels must continuously evolve as new targets and therapies emerge.
Related Content:
